Abstract
A novel tumor vaccine consisting of autologous formalin-fixed tumor fragments, cytokine-encapsulated microparticles, and an adjuvant was developed. Although mice experiments revealed mild efficacy, vaccination in a Phase I/IIa clinical trial of patients after resection of hepatocellular carcinoma resulted in significantly longer time before the first recurrence with no problematic adverse effect, than compared to historical control patients operated in the same department. In the followed academic Phase IIb randomized clinical trial, the vaccination significantly improved the recurrence-free survival and overall survival rates in a median follow-up of 15 months. The vaccine will be promising against recurrence of many types of human cancers after resection.
Keywords: cancer, cytokine, cytotoxic t lymphocyte, hepatocellular carcinoma, immunotherapy, overall survival, randomized clinical trial, tumor vaccine
Current Pharmaceutical Design
Title: Autologous Formalin-Fixed Tumor Vaccine
Volume: 11 Issue: 9
Author(s): T. Ohno
Affiliation:
Keywords: cancer, cytokine, cytotoxic t lymphocyte, hepatocellular carcinoma, immunotherapy, overall survival, randomized clinical trial, tumor vaccine
Abstract: A novel tumor vaccine consisting of autologous formalin-fixed tumor fragments, cytokine-encapsulated microparticles, and an adjuvant was developed. Although mice experiments revealed mild efficacy, vaccination in a Phase I/IIa clinical trial of patients after resection of hepatocellular carcinoma resulted in significantly longer time before the first recurrence with no problematic adverse effect, than compared to historical control patients operated in the same department. In the followed academic Phase IIb randomized clinical trial, the vaccination significantly improved the recurrence-free survival and overall survival rates in a median follow-up of 15 months. The vaccine will be promising against recurrence of many types of human cancers after resection.
Export Options
About this article
Cite this article as:
Ohno T., Autologous Formalin-Fixed Tumor Vaccine, Current Pharmaceutical Design 2005; 11 (9) . https://dx.doi.org/10.2174/1381612053507620
DOI https://dx.doi.org/10.2174/1381612053507620 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Systemic Therapeutic Gene Delivery for Cancer: Crafting Paris Arrow
Current Gene Therapy STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Molecular Imaging of Breast Cancer: Role of RGD Peptides
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: GPCR-Targeted Drug Development)
Current Drug Targets FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth
Anti-Cancer Agents in Medicinal Chemistry A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors
Central Nervous System Agents in Medicinal Chemistry TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design Preparation, Characterization and Drug Release of Salicylic Acid Loaded Porous Electrospun Nanofibers
Recent Patents on Nanotechnology